OceanTech Acquisitions I Corp: On October 12, Following Hearing, Co Received Letter From Nasdaq Stating That Co Regained Compliance Under MVLS Rule
$OTEC
Blank Checks
Finance
- SEC Filing
- SEC Filing
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
4 - OceanTech Acquisitions I Corp. (0001846809) (Issuer)
3 - OceanTech Acquisitions I Corp. (0001846809) (Issuer)
3 - OceanTech Acquisitions I Corp. (0001846809) (Issuer)
OceanTech Acquisitions I Corp. ("OceanTech" or the "Company") (NASDAQ:OTEC), a special purpose acquisition company, today announced that on May 30, 2023, at the special meeting of the stockholders of the Company, holders of 1,035,788 shares of Class A common stock of the Company (the "Redeeming Stockholders") exercised the right to redeem such shares. On June 2, 2023, the Company made cash payments to the Redeeming Stockholders totaling $11,233,820 representing approximately $10.84 per share. Following such payments to the Redeeming Stockholders, the Company's trust account had a balance of approximately $8,814,443. About OceanTech Acquisitions I Corp. OceanTech is a blank check company
OceanTech Acquisitions I Corp. ("OceanTech" or the "Company") (NASDAQ:OTEC), a special purpose acquisition company, previously filed a definitive proxy statement / final prospectus with respect to a special meeting of its stockholders to be held on Friday, May 26, 2023 at 1:00 p.m. EDT (the "Special Meeting") to vote on, among other things, a proposal to approve an amendment to OceanTech's amended and restated certificate of incorporation to extend the date by which OceanTech must consummate its initial business combination from June 2, 2023 by up to twelve (12) one-month extensions through June 2, 2024, or such earlier date as determined by OceanTech's board of directors. The Company is
Regentis Biomaterials Ltd ("Regentis") is a regenerative medicine company dedicated to developing innovative tissue repair solutions that restore the health and enhance quality of life of patients. Regentis' lead product is GelrinC, a cell-free, off-the-shelf hydrogel that is cured into a resorbable implant in the knee for the treatment of painful injuries to articular knee cartilage. There is currently no approved off-the-shelf product marketed in the United States for cartilage repair. GelrinC is already approved as a device with a CE mark in Europe, and Regentis is currently conducting a pivotal trial, under the FDA sanctioned protocol, in the United States and Europe. The transac
425 - OceanTech Acquisitions I Corp. (0001846809) (Subject)
8-K - OceanTech Acquisitions I Corp. (0001846809) (Filer)
425 - OceanTech Acquisitions I Corp. (0001846809) (Subject)
Regentis Biomaterials Ltd ("Regentis") is a regenerative medicine company dedicated to developing innovative tissue repair solutions that restore the health and enhance quality of life of patients. Regentis' lead product is GelrinC, a cell-free, off-the-shelf hydrogel that is cured into a resorbable implant in the knee for the treatment of painful injuries to articular knee cartilage. There is currently no approved off-the-shelf product marketed in the United States for cartilage repair. GelrinC is already approved as a device with a CE mark in Europe, and Regentis is currently conducting a pivotal trial, under the FDA sanctioned protocol, in the United States and Europe. The transac
SC 13G/A - OceanTech Acquisitions I Corp. (0001846809) (Subject)
SC 13G/A - OceanTech Acquisitions I Corp. (0001846809) (Subject)
SC 13G/A - OceanTech Acquisitions I Corp. (0001846809) (Subject)